
## Leigha Senter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2045904/publications.pdf Version: 2024-02-01



LEICHA SENTER

#	Article	IF	CITATIONS
1	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation. Journal of Clinical Oncology, 2014, 32, 1547-1553.	1.6	523
2	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1</i> / <i>2</i> (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
3	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology, 2008, 135, 419-428.e1.	1.3	480
4	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
5	ldentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
7	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
8	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
9	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
10	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	160
11	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
12	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. JAMA Oncology, 2018, 4, 1059.	7.1	121
13	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
14	A genome-wide association study yields five novel thyroid cancer risk loci. Nature Communications, 2017, 8, 14517.	12.8	117
15	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	6.4	101
16	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
17	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
18	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88

LEIGHA SENTER

#	Article	IF	CITATIONS
19	GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. Nature Communications, 2020, 11, 3981.	12.8	86
20	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
21	Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Nondiscrimination Act. Familial Cancer, 2012, 11, 637-644.	1.9	66
22	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2018, 150, 85-91.	1.4	65
23	Factors influencing ovulation and the risk of ovarian cancer in <scp><i>BRCA1</i></scp> and <scp><i>BRCA2</i></scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	5.1	56
24	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study. Breast Cancer Research and Treatment, 2016, 155, 365-373.	2.5	55
25	Somatic <i>MED12</i> mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 1884-1888.	1.8	49
26	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
27	Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4005-4013.	3.6	47
28	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. Gynecologic Oncology, 2017, 147, 110-114.	1.4	46
29	Thyroglobulin Liquid Chromatography–Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies. Thyroid, 2017, 27, 74-80.	4.5	44
30	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
31	Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters. Thyroid, 2016, 26, 1276-1284.	4.5	32
32	HABP2 G534E Variant in Papillary Thyroid Carcinoma. PLoS ONE, 2016, 11, e0146315.	2.5	31
33	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
34	Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 2009, 8, 501-504.	1.9	16
35	"Second lass Status?―Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome. Journal of Genetic Counseling, 2018, 27, 885-893.	1.6	16
36	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass ), 2012, 18, 334-337.	2.0	13

LEIGHA SENTER

#	Article	IF	CITATIONS
37	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	2.5	12
38	Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532.	6.4	12
39	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	1.9	11
40	An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genetics in Medicine, 2019, 21, 2706-2712.	2.4	11
41	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	2.5	10
42	Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. Hormones and Cancer, 2018, 9, 433-439.	4.9	10
43	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	1.4	10
44	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International Journal of Gynecological Cancer, 2020, 30, 1569-1575.	2.5	10
45	Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer, 2022, 128, 654-664.	4.1	10
46	Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Translational Behavioral Medicine, 2020, 10, 337-346.	2.4	9
47	Advancing the genetic counseling profession through research: Identification of priorities by the National Society of Genetic Counselors research task force. Journal of Genetic Counseling, 2020, 29, 884-887.	1.6	9
48	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. Menopause, 2020, 27, 1396-1402.	2.0	8
49	Variants in microRNA genes in familial papillary thyroid carcinoma. Oncotarget, 2017, 8, 6475-6482.	1.8	8
50	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	1.4	8
51	National Society of Genetic Counselors Code of Ethics: Explication of 2017 Revisions. Journal of Genetic Counseling, 2018, 27, 9-15.	1.6	7
52	Understanding <i>BRCA</i> Mutation Carriers' Preferences for Communication of Genetic Modifiers of Breast Cancer Risk. Journal of Health Communication, 2019, 24, 377-384.	2.4	7
53	Risk assessment and genetic counseling for Lynch syndrome – Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling, 2022, 31, 568-583.	1.6	7
54	Nurse practitioners & amp; genetic counselors. Nurse Practitioner, 2016, 41, 43-49.	0.3	6

LEIGHA SENTER

#	Article	IF	CITATIONS
55	Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decisionâ€Making Process of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of Genetic Counseling, 2018, 27, 1291-1301.	1.6	6
56	The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation. Journal of Genetic Counseling, 2021, 30, 656-664.	1.6	6
57	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	2.5	6
58	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. Menopause, 2020, 27, 156-161.	2.0	5
59	Breast cancer risk after age 60 amongÂBRCA1 andÂBRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	2.5	5
60	Exploring genetic counselors' perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM). Journal of Genetic Counseling, 2019, 28, 664-672.	1.6	4
61	Fine mapping of 14q13 reveals novel variants associated with different histological subtypes of papillary thyroid carcinoma. International Journal of Cancer, 2019, 144, 503-512.	5.1	4
62	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	2.5	3
63	Weight Gain After Oophorectomy Among Women with a BRCA1 or BRCA2 Mutation. Women's Health, 2015, 11, 453-459.	1.5	2
64	Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake. Gynecologic Oncology, 2022, 164, 615-621.	1.4	2
65	Abstract 878: Contraceptive use and ovarian cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: A prospective cohort study. Cancer Research, 2021, 81, 878-878.	0.9	1
66	The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <scp><i>BRCA2</i> 6174delT</scp> . Clinical Genetics, 2022, 101, 317-323.	2.0	0